The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
Abstract
BACKGROUND: Glutathione conjugation of tacrine reactive metabolites depends in part on the activity of glutathione-S-transferases (GST), of which two isozymes (GST M1 and GST T1) are polymorphically expressed. OBJECTIVE AND METHODS: To determine whether GST M1, GST T1, and the combined GST M1 and GST T1 null genotypes predict individual susceptibility to tacrine hepatotoxicity, 141 patients with mild to moderate Alzheimer's disease treated with tacrine were genotyped. RESULTS: During the treatment period, 52 patients had elevated alanine aminotransferase (ALT) levels at least three times the upper limit of normal, whereas 89 patients had normal ALT values (< or = upper limit of normal). Both groups were comparable in demographic and clinical characteristics. Twenty-eight patients were found to be GST T1-negative (20%; with a 95% confidence interval [95% CI] from 13% to 27%), and 68 patients (48%; 95% CI from 40% to 57%) were GST M1-negative. The combined GST M1-T1 null genotype was observed in 18 patients (13%; 95% CI from 7% to 18%) of whom 13 had an elevated plasma ALT at least three times the upper limit of normal during the study period. Although the cumulative percentage of elevated plasma ALT tended to be higher in the GST M1 null genotype, neither GST M1 nor GST T1 alone could predict individual susceptibility to tacrine hepatotoxicity. Multivariate Cox hazards model showed that the association of the GST M1-T1 null genotype was an independent risk factor of hepatotoxicity. CONCLUSIONS: The presence of combined alleles M1 and T1 deficiencies in glutathione-S-transferase genes increases the susceptibility to tacrine hepatotoxicity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polymorphisms in this enzyme can impact the amount of oxidative DNA damage, and the M1 and T1 genetic polymorphisms are associated with greater hepatotoxicity49.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [49]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Pemble, S. E., Schroeder, K., Spencer, S. R., Meyer, D. J., Hallier, E., Bolt, H. M., KETTERER, B., & Taylor, J. B. (1994) · Biochemical Journal · doi:10.1042/bj3000271 · Cited by 1,296
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,000
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
A Controlled Trial of Tacrine in Alzheimer's Disease
Farlow, M. R. (1992) · JAMA · doi:10.1001/jama.268.18.2523 · Cited by 632
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Helzlsouer, K. J., Huang, H., Hoffman, S. C., Alberg, A. J., Comstock, G. W., Strickland, P. T., Selmin, O. I., Watson, M., & Bell, D. A. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.7.512 · Cited by 292
Bailey, L., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., & Parl, F. F. (1998) · PubMed · Cited by 212
Madden, S. F., Woolf, T. F., Pool, W. F., & Park, B. K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90342-t · Cited by 103
Brockmöller, J., Gross, D., Kerb, R., Drakoulis, N., & Roots, I. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90591-6 · Cited by 99
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking.
Jourenkova, N., Reinikainen, M., Bouchardy, C., Dayer, P., Benhamou, S., & Hirvonen, A. (1998) · PubMed · Cited by 97
Combined genetic polymorphism and risk for development of lung cancer
El‐Zein, R. A., Zwischenberger, J. B., Wood, T. G., Abdel‐Rahman, S. Z., Brekelbaum, C., & Au, W. W. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00166-8 · Cited by 81
Woolf, T. F., Pool, W. F., Bjorge, S. M., Chang, T., Goel, O. P., Purchase, C. F., Schroeder, M. C., Kunze, K. L., & Trager, W. F. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08177-2 · Cited by 63
Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans*
Becquemont, L., Ragueneau, I., Bot, M. A. L., Riché, C., Funck‐Brentano, C., & Jaillon, P. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90095-3 · Cited by 55
Trizna, Z., de Andrade, M., Kyritsis, A. P., Briggs, K. L., Levin, V. A., Bruner, J. M., Wei, Q., & Bondy, M. L. (1998) · PubMed · Cited by 51
Warholm, M., Rane, A., Alexandrie, A.-K., Monaghan, G., & Rannug, A. (1995) · Pharmacogenetics · doi:10.1097/00008571-199508000-00010 · Cited by 49
Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on lung cancer risk in smokers
Jourenkova, N., Reinikanen, M., Bouchardy, C., Husgafvel‐Pursiainen, K., Dayer, P., Benhamou, S., & Hirvonen, A. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00010 · Cited by 45
Glutathione S‐transferase mu genotype (GSTM1*0) in Alzheimer's patients with tacrine transaminitis.
Green, V., Pirmohamed, M., Kitteringham, N. R., Knapp, M., & Park, B. K. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04470.x · Cited by 44
Lear, J. T. (1997) · Carcinogenesis · doi:10.1093/carcin/18.8.1499 · Cited by 39
Induction of tumor necrosis factor-? as a cause of bleomycin-related toxicity
Sleijfer, S., Vujašković, Ž., Limburg, P. C., Koops, H. S., & Mulder, N. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5 · Cited by 37
Yilmaz, A., Bieler, G., Spertini, O., Lejeune, F. J., & Rüegg, C. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980812)77:4 · Cited by 34
Becquemont, L., Bot, M. A. L., Richeb, C., Funck‐Brentano, C., Jaillon, P., & Beaune, P. H. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00002 · Cited by 34
Sousa, M. D., Pirmohamed, M., Kitteringham, N. R., Woolf, T. F., & Park, B. K. (1998) · Pharmacogenetics · doi:10.1097/00008571-199808000-00009 · Cited by 20
Becquemont, L., Lecoeur, S., Simon, T., Beaune, P. H., Funck‐Brentano, C., & Jaillon, P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00011 · Cited by 11
Self-citation
Flagged first, then by citations
1 of the 25 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 480
Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity
Russmann, S., Kullak-Ublick, G. A., & Grattagliano, I. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803097 · Cited by 412
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges
Wilke, R. A., Lin, D. W., Roden, D. M., Watkins, P. B., Flockhart, D. A., Zineh, I., Giacomini, K. M., & Krauss, R. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2423 · Cited by 400
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Metadata
- Authors
- Simon, T.
- Affiliations
- Inserm (FR)
- Corresponding author
- Simon, T
- ORCID
- Simon, T
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-04
- Volume
- 67
- Issue
- 4
- Pages
- 432-437
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2015114639
- Cited by
- 122
- References
- 25
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 5 · 2014: 1 · 2013: 6 · 2012: 4
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- tacrine, hepatotoxicity, glutathione S-transferase M1, glutathione S-transferase T1, genetic polymorphism, Alzheimer's disease, drug-induced liver injury, glutathione conjugation, alanine aminotransferase, pharmacogenetics, drug sensitivity
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Female, Genotype, Glutathione Transferase, Humans, Isoenzymes, Liver, Liver Function Tests, Male, Parasympathomimetics, Pharmacogenetics, Polymorphism, Genetic, Tacrine, Proportional Hazards Models, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
